[Latin Name]  Citrus aurantium L.

[Specification] Synephrine 4.0%–80%

[Appearance] Yellow brown powder

Plant Part Used: Fruit

[Particle size] 80Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

[What is Citrus Aurantium]

Citrus aurantium L, belonging to the family Rutaceae, is widely distributed in China. Zhishi, the Chinese traditional name for Citrus aurantium, has long been a folk medicine in traditional Chinese medicine (TCMto improve indigestion and help stimulate the Qi (energy force).

[Function]

1. Have the function of antioxidant, anti-inflammatory, hypolipidemic, vasoprotective and anticarcinogenic and cholesterol lowering actions.

2. Have the function of inhibiting following enzymes: Phospholipase A2, lipoxygenase, HMG-CoA reductase and cyclo-oxygenase.

3. Have the function of improving the health of capillaries by reducing the capillary permeability.

4. Have the function of reducing hay fever and other allergic conditions by inhibiting the release of histamine from mast cells. The possible activity of hesperidin could be explained by the inhibition of polyamine synthesis. (bitter orange extract)

Quinoa & Nuts Energy Bar

oat powder 60g
whole-wheat flour 40g
salt a pinch
flaxseed 15g
quinoa 30g
dried cranberries 30g
raisins 30g
walnuts 30g
pumpkin seeds 30g
honey 30g
water 25g

1) Rinse the quinoa on a fine mesh filter and soak in hot water for 5 mins. Strain.
2) Mix all the ingredients together.
3) Spread them evenly on a baking sheet on a pan.
4) Bake for 25 mins. at 160℃. Let cool then slice into desired size.

——————————————————————————————-

Twitter https://twitter.com/liangshi_proj
Website https://www.liangshi.com.tw/
Facebook https://www.facebook.com/liangshiproject/
Instagram https://www.instagram.com/liangshi.project/
Pinterest https://www.pinterest.com/liangshiproject/
Medium https://medium.com/@liangshi_proj

Title: Pneumococcal infections and vaccination.
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia, Spain

OMICS International: https://omicsonline.org
Vaccine Conferences: https://conferenceseries.com/immunolog…
Global Medical Conferences: https://conferenceseries.com
Global Pharmaceutical Conferences: https://pharmaceuticalconferences.com
Global Cancer Conferences: https://cancersummit.org
Global Diabetes Conferences: https://diabetesexpo.com
Global Dental Conferences: https://dentalcongress.com
Global Nursing Conferences: https://nursingconference.com

Abstract
Pneumococci are major contributors to morbidity and mortality worldwide. They are the major cause of milder respiratory tract infections such as otitis and sinusitis, but also to more severe invasive infections such as community-acquired pneumonia with associated septicemia and meningitis. Even though being a devastating pathogen, pneumococci are also common colonizers of the upper respiratory tract of healthy children where from they may spread to cause disease. Risk groups for acquiring an invasive pneumococcal infection (IPD) include preschool children and the elderly, as well as immunocompromised individuals, splenectomised, and patients with a previous influenza virus infection. Several bacterial virulence factors have been described for pneumococci of which a major one is the capsular polysaccharide. Depending on differences in these capsular structures so far more than 90 different serotypes have been distinguished. Recently so called conjugated vaccines (PCV) have been introduced into the child hood vaccination program in many countries. These vaccines are based on a limited amount (7, 10 or 13) of the capsular serotypes. In Sweden PCVs were introduced in the whole of Sweden year 2009. Vaccine introduction has led to a reduction in the incidence of IPD in vaccinated children but also to serotype replacementand an increase of non-vaccine type disease.

Biography

Birgitta Henriques Normark is professor and head physician in Clinical microbiology at Karolinska Institute and Karolinska University hospital, as well as head physician at the Public Health Agency of Sweden. She is also vice dean for recruitment at Karolinska Institutet and a board member of the Swedish Research Council, Medicine and Health.Her research focuses on epidemiology, antibiotic resistance and host-microbe interactions in bacterial infections with special focus on pneumococcal epidemicity, molecular epidemiology, and mechanisms of invasive disease, innate immunity and host-microbe interactions determining disease outcome. The research has been published in 136 publications of which 107 are original peer reviewed articles.